Impact of Toll-Like Receptor 9 Agonist Class on Immunologic Effects in a Model of Liver Metastases with Pressure-Enabled Drug Delivery Regional infusion

被引：0
|
作者：
Cournoyer, Lauren
Ghosh, Chandra C.
Liu, Yujia
Ballarin, Alizee
Laporte, Jason
Guha, Prajna
Cox, Bryan F.
Katz, Steven C.
机构：
[1] Brown Univ, Warren Alpert Med Sch, Providence, RI USA
[2] Trisalus Life Sci, Westminster, CO USA
来源：
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS | 2023年 / 237卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
引用
收藏
页码：S472 / S473
页数：2
相关论文
共 9 条
  • [1] Pressure-Enabled Drug Delivery (PEDD) of a class C TLR9 agonist in combination with checkpoint inhibitor therapy in a murine pancreatic cancer model
    Capacio, Benedict A.
    Narayanan, Jayanth S. Shankara
    Vicente, Diego A.
    Liu, Yujia
    LaPorte, Jason P.
    Cox, Bryan F.
    Jaroch, David B.
    Katz, Steven C.
    White, Rebekah R.
    SURGERY, 2023, 174 (03) : 666 - 673
  • [2] Pressure-Enabled Drug Delivery (Pedd) of a Class C TLR9 Agonist in Combination With Checkpoint Inhibitor Therapy in a Pancreatic Cancer Murine Model
    Vicente, Diego
    Capacio, Benedict
    Narayanan, Jayanth Shankara
    Liu, Yujia
    LaPorte, Jason
    Cox, Bryan
    Jaroch, David
    Katz, Steven
    White, Rebekah
    ANNALS OF SURGICAL ONCOLOGY, 2023, 30 (SUPPL 1) : S110 - S110
  • [3] Pressure-Enabled Drug Delivery (PEDD) of a class C TLR9 agonist in combination with checkpoint inhibitor therapy in a murine pancreatic cancer model.
    Capacio, Benedict
    Narayanan, Jayanth Shankara
    Vicente, Diego
    Liu, Yujia
    LaPorte, Jason
    Cox, Bryan
    Jaroch, David
    Katz, Steven
    White, Rebekah Ruth
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 729 - 729
  • [4] Improved trafficking and tumor control with regional, pressure-enabled drug delivery of anti-CEA CAR-T cells for colorectal liver metastases in a murine model
    Chai, Louis F.
    Hardaway, John C.
    Heatherton, Kara R.
    O'Connell, Kyle P.
    LaPorte, Jason P.
    Guha, Prajna
    Saied, Abdul
    Knight, Robert
    Jaroch, David
    Cox, Bryan F.
    Katz, Steven C.
    JOURNAL OF IMMUNOLOGY, 2020, 204 (01):
  • [5] PERIO-01: Initial safety experience and immunologic effects of a Class C TLR9 agonist using pressure-enabled drug delivery in a phase 1 trial of hepatic arterial infusion of SD-101+/- checkpoint inhibition in metastatic uveal melanoma
    Patel, Sapna P.
    Haymaker, Cara
    Sheth, Rahul A.
    Kuban, Joshua D.
    Weintraub, Joshua
    Wehrenberg-Klee, Eric
    Novelli, Paula
    Gonsalves, Carin
    Adamo, Robert
    Honaker, Virgina
    Timciuc, Laura
    Hennegan, Tarin
    Molina, Juan C. Amador
    Duose, Dzifa
    Cuenta, Edwin R. Parras
    Lucci, Anthony
    Meas, Salyna
    Sarli, Vanessa
    Prieto, Victor G.
    LaPorte, Jason
    Hulstine, Ann-Marie
    Moody, Ashley
    Cox, Bryan
    Geller, David
    Davar, Diwakar
    Montazeri, Kamaneh
    Orloff, Marlana
    Katz, Steven C.
    Carvajal, Richard
    CANCER RESEARCH, 2023, 83 (07)
  • [6] IMPACT OF SD-101, A TOLL-LIKE RECEPTOR 9 CLASS C (TLR9C), AGONIST ON MYELOID DERIVED SUPPRESSOR CELLS
    Ghosh, Chandra
    Katz, Steven
    Ghosh, Chandra
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A1208 - A1208
  • [7] Impact of Pressure-Enabled Drug Delivery (PEDD) of Nelitolimod (SD-101) into the Liver with Systemic Immune Checkpoint Inhibitor (ICI) for Treating Metastatic Uveal Melanoma with Liver Metastases (MUM-LM)
    Layman, Ilan
    Ghosh, Chandra C.
    Cournoyer, Lauren
    Guha, Prajna
    Laporte, Jason
    Ballarin, Alizee
    Morrissey, Molly
    Fraser, Kayla M.
    Cox, Bryan F.
    Katz, Steven C.
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2024, 239 (05) : S446 - S446
  • [8] An agonist of Toll-like receptor 5 sustains hepatic natural killer and dendritic cell recruitment to the liver while eliciting anti-cancer effects against liver metastases
    Brackett, Craig
    Kojouharov, Bojidar
    Gitlin, Ilya
    Johnson, Christopher
    Burdelya, Lyudmila
    Gudkov, Andrei
    JOURNAL OF IMMUNOLOGY, 2013, 190
  • [9] Safety and early biologic effects of phase 1 PERIO-01 trial of pressure-enabled drug delivery (PEDD) of TLR9 agonist SD-101 and immune checkpoint inhibition (ICI) in uveal melanoma metastatic to the liver (MUM)
    Montazeri, Kamaneh
    Davar, Diwakar
    Haymaker, Cara L.
    Sheth, Rahul
    Kuban, Joshua
    Weintraub, Joshua
    Wehrenberg-Klee, Eric
    Novelli, Paula M.
    Gonsalves, Carin F.
    Adamo, Robert D.
    Lucci, Anthony
    Meas, Salyna
    Sarli, Vanessa Nicole
    Prieto, Victor Gerardo
    Geller, David A.
    Orloff, Marlana M.
    Carvajal, Richard D.
    Patel, Sapna Pradyuman
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
1